Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGPhase 3INTERVENTIONAL

Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The aim of this clinical trial is to evaluate the effect of low doses of antiplatelet medications (aspirin 81 mg/day or clopidogrel 75 mg/day) with or without a combination of antioxidants (N-acetylcysteine 600 mg/day) in a dry AMD patient with large drusen. Participants will divided in to three groups. * Participants who were already taking low dose antiplatelet medications. * Participants who take the antiplatelet drug mentioned above in addition to the antioxidant prescribed by the investigator * Participants does not use any medications.

Who May Be Eligible (Plain English)

Who May Qualify: - Dry AMD with at least 1 large drusen. According to the AREDS study, large drusen have a size of more than 125 micron. - Patients can evaluate SD-OCT (Spectral domain optical coherence tomography), OCT angiography, and best-corrected visual acuity. - Age range: 50-85 years - Patients who have previously used antiplatelet drugs. Who Should NOT Join This Trial: - Patient with advanced AMD, such as geographic atrophy, neovascular complications (choroidal neovascularization) - Patient with additional retinal diseases that affect visual acuity, e.g., retinal detachment, diabetic macular edema. - Patient with a history of intravitreal anti-VEGF injection or macular laser. - Patient using SSRIs, SNRIs, azole, NSAIDs, dual antiplatelet, anticoagulant medications. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Dry AMD with at least 1 large drusen. According to the AREDS study, large drusen have a size of more than 125 micron. * Patients can evaluate SD-OCT (Spectral domain optical coherence tomography), OCT angiography, and best-corrected visual acuity. * Age range: 50-85 years * Patients who have previously used antiplatelet drugs. Exclusion Criteria: * Patient with advanced AMD, such as geographic atrophy, neovascular complications (choroidal neovascularization) * Patient with additional retinal diseases that affect visual acuity, e.g., retinal detachment, diabetic macular edema. * Patient with a history of intravitreal anti-VEGF injection or macular laser. * Patient using SSRIs, SNRIs, azole, NSAIDs, dual antiplatelet, anticoagulant medications.

Treatments Being Tested

DRUG

Aspirin 81Mg Ec Tab

Patients take aspirin 81 mg per day.

DRUG

Clopidogrel

Patients take clopidogrel 75 mg per day.

DRUG

N-acetylcysteine

Patients are given N-acetylcysteine 600 mg per day.

Locations (1)

Department of ophthalmology, Faculty of medicine, Vajira hospital, Navamindradhiraj University
Bangkok, Dusit, Thailand